Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-12-02
2009-08-11
Bunner, Bridget E (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007900, C435S007910, C435S007920, C436S173000, C436S174000, C436S501000
Reexamination Certificate
active
07572596
ABSTRACT:
The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.
REFERENCES:
patent: 6618138 (2003-09-01), Khoury
patent: 6776984 (2004-08-01), Schwartz
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/59360 (1998-12-01), None
Ranganathan et al., J Neurochem. 2005; 29: 1461-1471.
Yokota et al., Acta Neuropathol. 2006; 112: 633-645.
Aizawa et al., J. Neuro Sci. 2000; 175: 109-113.
Wada et al. Acta Neuropathol. 1999; 98: 150-156.
Berg et al. Exploring Proteins, in Biochemistry, fifth edition, 2002 by W. H. Freeman and Company, New York, New York, 10010; relevant chapter portions downloaded on Jan. 14, 2007 at ncbi.nlm.nih.gov/books/bv.fcgi?highlight=immunological%20techniques&rid=stryer.section.506#507; 10 pages total downloaded.
Ono et al. Acta Neurol Scand. 2000; 102: 47-52.
Cudkowicz et al., “Measures and Markers in Amyotrophic Lateral Sclerosis,”NeuroRX: The Journal of the American Society for Experimental NeuroTherapeutics, 1(2): 273-283 (Apr. 2004).
Abrahamson, et al., “The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20”,Hum. Genet., 82(3):223-6 (1989).
Asgeirsson, et al., “Hereditary cystatin C amyloid angiopathy: monitoring the presence of the Leu-68 —> Gln cystatin C variant in cerebrospinal fluids and monocyte cultures by MS”,Biochem. J., 329 (Pt 3):497-503 (1998).
Carrette, et al., “A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease”,Proteomics, 3(8):1486-94 (2003).
Deng, et al., “Elevation of cystatin C in susceptible neurons in Alzheimer's disease”,Am. J. Pathol., 159(3):1061-8 (2001).
Kato, et al., “A neurosphere-derived factor, cystatin C, supports differentiation of ES cells into neural stem cells”,Proc. Natl. Acad. Sci. U.S.A., 103(15):6019-24 (2006).
Lofberg, et al., “Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis”,Stroke, 18(2):431-40 (1987).
Nagai, et al., “Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases”,Neurology, 55(12):1828-32 (2000).
Okamoto, et al., “Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum”,Neurosci. Lett., 162(1-2):125-8 (1993).
Sanchez, et al., “Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease”,Proteomics, 4(8):2229-33 (2004).
XU, et al., “Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies”,Neurobiol. Dis., 18(1):152-65 (2005).
U.S. Appl. No. 11/294,326, filed Dec. 2, 2005, Bowser.
U.S. Appl. No. 60/513,930, filed Oct. 23, 2003, Bowser et al.
U.S. Appl. No. 60/632,380, filed Dec. 2, 2004, Bowser.
Arrahamson et al., “Structure and Expression of the Human Cystatin C Gene,”The Biochemical Journal, 268(2): 287-294 (Jun. 1, 1990).
Benson et al., “Identification of Carriers of a Variant Plasma Prealbumin (Transthyretin) Associated With Familial Amyloidotic Polyneuropathy Type I,”The Journal of Clinical Investigation, 75: 71-75 (1985).
Bergen et al., “Identification of Transthyretin Variants by Sequential Proteomic and Genomic Analysis,”Clinical Chemistry, 50(9): 1544-1552 (2004).
Bernstein et al., “Transthyretin: Its Response to Malnutrition and Stress Injury”Clin Chem Lab Med, 40(12): 1344-1348 (2002).
Borchelt et al., “Superoxide Dismutase 1 With Mutations Linked to Familial Amyotrophic Lateral Sclerosis Possesses Significant Activity,”Proc. Natl. Acad. Sci. USA, 91(17): 8292-8296 (Aug. 16, 1994).
Bowser et al., “Protein Profiling of Amyotrophic Lateral Sclerosis Patients by Mass Spectrometry,”the FASEB Journal, 17(4). A658 (2003).
Chaudhuri et al., “The Neuroendocrine Protein 7B2 Acts as a Molecular Chaperone in the In Vitro Folding of Human Insulin-Like Growth Factor-1 Secreted From Yeast,”Biochemical and Biophysical Research Communications, 211(2): 417-425 (Jun. 15, 1995).
Cleveland et al., “From Charcot to Lou Gehrig: Deciphering Selective Motor Neuron Death in ALS,”Nature Review Neuroscience, 2: 806-819 (Nov. 2001).
Connors et al., “Tabulation of Human Transthyretin (TTR) Variants, 2003,”Amyloid, 10(3): 160-184 (Sep. 2003).
Corcoran et al., “Absence of Retinoids Can Induce Motoneuron Disease in the Adult Rat and a Retinoid Defect is Present in Motoneuron Disease Patients,”Journal of Cell Science, 115(24): 4735-4741 (Dec. 15, 2002).
Desnuelle et al., “A Double-Blind, Placebo-Controlled Randomized Clinical Trial of α- Tocopherol (Vitamin E) in the Treatment of Amyotrophic Lateral Sclerosis,”ALS and Other Motor Neuron Disorders, 2(1): 9-18 (2001).
Feigenbaum et al., “Dentral and Meta-Dendral: Roots of Knowledge Systems and Expert System Applications,”Artificial Intelligence, 59: 233-240 (1993).
Fernandez et al., “Thyroid Hormone Administration Enhances Remyelination in Chronic Demyelinating Inflammatory Disease,”Proc. Natl. Acad. Sci. USA, 101(46): 16363-16368 (Nov. 16, 2004).
Goodall et al., “Association of the H63D Polymorphism in the Hemochromatosis Gene with Sporadic ALS,”Neurology, 65(6): 934-937.
Groeneveld et al., “A Randomized Sequential Trail of Creatine in Amyotrophic Lateral Sclerosis,”Annals of Neurology, 53(4): 437-445 (Apr. 2003).
Gurney et al., “Motor Neuron Degeneration in Mice that Express a Human Cu, Zn Superoxide Dismutase Mutation,”Science, 264: 1772-1775 (Jun. 17, 1994).
Gurney et al., “Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis,”Annals of Neurology, 39(2): 147-157 (Feb. 1996).
Hillenkamp et al., “Matrix Assisted UV-Laser Desorption/Ionization: A New Approach to Mass Spectrometry of Large Biomolecules,”Biological Mass Spectrometry, (Burlingame and McCloskey, eds) Elsevier, Amsterdam, 49-60 (1990).
Jellinger, “Neuropathological Spectrum of Synucleinopathies,”Movement Disorders, 18(Supplement6): S2-S12 (2003).
Kamel et al., “Lead Exposure and Amyotrophic Lateral Sclerosis,”Epidemiology, 13(3): 311-319 (May 2002).
Kim et al., “PARP Expression is Increased in Astrocytes but Decreased in Motor Neurons in the Spinal Cord of Sporadic ALS Patients,”Journal of Neuropathology and Experimental Neurology, 62(1): 88-103 (Jan. 2003).
Kriz et al., “Efficient Three-Drug Cocktail for Disease Induced by Mutant Superoxide Dismutase,”Annals of Neurology, 53(4): 429-436 (Apr. 2003).
Lee et al., “Carcinogenicity Predictions for a Group of 30 Chemicals Undergoing Rodent Cancer Bioassays Based on Rules Derived from Subchronic Organ Toxicities,”Environmental Health Perspectives, 104(Supplement5): 1059-1063 (Oct. 1996).
Levy et al., “Stroke in Icelandic Patients with Hereditary Amyloid Angiopathy is Related to a Mutation in the Cystatin C Gene, An Inhibitor of Cysteine Proteases,”The Journal of Experimental Medicine, 169(5): 1771-1778 (May 1, 1989).
Lin et al., “Large-scale pr
Borgeest Christina
Bunner Bridget E
Pabst Patent Group LLP
University of Pittsburgh of the Commonwealth System of Higher Ed
LandOfFree
Modulation of the neuroendoctrine system as a therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of the neuroendoctrine system as a therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of the neuroendoctrine system as a therapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107182